Sagimet gets FDA clearance for phase 3 acne trial of denifanstat
Tweet Send to a Friend
Sagimet Biosciences Inc. (NASDAQ: SGMT) announced that the U.S. Food and Drug Administration has cleared the company's Investigational New Drug ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


